Mylan launches generic Viramune XR

PITTSBURGH — Mylan on Friday announced the launch of nevirapine extended-release tablets in 400-mg strength, a generic version of Viramune XR from Boehringer Ingelheim. The drug is a combination antiretroviral treatment for HIV-1 infection in adults and in children six to less than 18 years of age, the company said. 

 

Nevirapine extended-release tablets in 400-mg dosage strength had sales in the United States of $61.9 million for the 12 months ending Sept. 30, 2014, according to IMS Health data.